Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
giovedì, ottobre 01
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Nautilus Biotechnology Inc
NAUT
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$1.42
0.055
4.03%
Ult. Agg.: Oct 1, 7:33 AM
$1.42
0.055
4.03%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Privacy Manager
Nautilus Biotechnology Financials
Nautilus Biotechnology (NAUT) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Nautilus Biotechnology Q2 EPS $(0.11) Beats $(0.14) Estimate, Sales $190.000K
Nautilus Biotechnology (NASDAQ:NAUT) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 8.33 percent increase over losses of $(0.12) per share
Benzinga Newsdesk
Earnings Scheduled For April 28, 2026
Benzinga Insights
PRO
Nautilus Biotechnology Q1 EPS $(0.12) Beats $(0.17) Estimate
Nautilus Biotechnology (NASDAQ:NAUT) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.17) by 25 percent. This is a 7.69 percent increase over losses of $(0.13) per share
Benzinga Newsdesk
PRO
Nautilus Does Not Anticipate Material Revenue In 2026 From Early Access Program Engagement
Benzinga Newsdesk
PRO
Nautilus Biotechnology Q4 EPS $(0.11) Beats $(0.14) Estimate
Nautilus Biotechnology (NASDAQ:NAUT) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 21.43 percent increase over losses of $(0.14) per share
Benzinga Newsdesk
Earnings Scheduled For October 28, 2025
Benzinga Insights
